PDC drugs set off a fever for research and development, and large pharmaceutical companies are competing for layout

PDC (Peptide-Drug Conjugate), that is, peptide-conjugated drugs, has a smaller molecular weight than antibody-conjugated drugs (Antibody Drug Conjugate, ADC), and is less likely to cause autoimmune reactions; compared with the complex process of antibody production , PDC is easier to synthesize and purify, effectively reducing the cost of large-scale production and other advantages, it has gradually begun to become an outstanding candidate in the next wave of targeted drug development
.
Currently, there are two PDC drugs on the market worldwide, one of which is Lutathera developed by Advanced Accelerator Applications SA, a subsidiary of Novartis, and is the world's first peptide receptor radionuclide therapy (PRRT) drug
.
Data show that Lutathera is a somatostatin analog peptide labeled with lutetium Lu 177, which acts by binding to a cell called somatostatin receptor, which may be present in some tumors.
On
.
The other is Pepaxto from Oncopeptides, a Swedish biotech company
.
The drug is the first anti-cancer peptide conjugate drug approved by the FDA.
It received accelerated FDA approval on February 26 this year.
It is used in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM) adults Patient
.
However, only 8 months after this approval, Pepaxto has encountered voluntary withdrawal from the market
.
It is understood that with the failure of the Phase III OCEAN study of the drug, oncopeptides has announced its decision to withdraw Pepaxto from the US market
.
However, although there are few successfully marketed drugs and the risk of withdrawal from the market, it has more advantages than ADC drugs; at present, the PDC field is still attracting more and more pharmaceutical companies' attention
.
Among them, in addition to large multinational pharmaceutical companies such as Novartis, AstraZeneca, and Roche, there are also a large number of biopharmaceutical companies from China, such as Shengnuoji Pharmaceutical, Mainstream Bio, Tongyi Pharmaceutical, and Taierkang Bio, are continuously increasing.
Incoming
.
Overall, the current PDC's products to overseas companies in the research-based, rapid progress in the development of companies, including Oncopeptipes, Bicycle Therapeutics, Cybrexa Therapeutics and so on
.
In China, Sheng Nuoji Pharmaceuticals is a PDC enterprise that has made rapid progress
.
It is reported that the SNG1005, developed in cooperation with the Canadian company Angiochem, is carrying out a phase III clinical trial in China, and has shown positive clinical treatment in the completed phase II treatment of breast cancer and papillary metastases and recurrent breast cancer and brain parenchymal metastases.
Effect
.
Among them, in the treatment of intracranial and extracranial breast cancer patients with brain metastases, the clinical benefit rates of this product have reached 77% and 86%, respectively
.
In addition, Tongyi Medicine has developed a series of anti-tumor conjugate drugs with the core technology platform BESTTM.
Among them, the PDC drug CBP-1008 has made rapid progress and is undergoing phase I clinical trials.
In addition, mainstream biology and Taierkang Biotechnology PDC drugs are also in the pre-clinical development stage
.
In general, with continuous breakthroughs in technology, PDC is growing into an emerging potential track
.
The industry predicts that PDC may become the next stop for more conjugated drug R&D companies in the future in the face of the ADC race track that has already gotten together
.
As more and more companies at home and abroad devote themselves to related research and development, more PDC drugs are expected to come out as soon as possible, benefiting the majority of patients
.